Compare Abbott Laboratories (ABT) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Yum China Holdings Inc — how do they compare? Abbott Laboratories trades at $95.36 (market cap $166.94B), while Yum China Holdings Inc trades at $42.85 (market cap $14.58B). The key difference: Abbott Laboratories is far larger — about 11.4× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| ABT | YUMC | |
|---|---|---|
Market Cap | $166.94B | $14.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $57.95 |
52-Week Low | $82.57 | $40.18 |
Enterprise Value | $193.69B | $15.47B |
Dividend Yield | 2.63% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
YUMC trades at $42.22, up 1.25% today, with a bullish technical signal despite mixed moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.87 exceeding the $0.854 estimate. Revenue grew to $11.80B in 2025, and the stock trades at a P/E of 16.28. Recent news highlights YUMC's acquisition of Pizza Hut brand rights in mainland China and a $512 million share repurchase plan.
The outlook is positive given consistent earnings outperformance, strategic brand control expansion, and shareholder returns. Risks include China's competitive consumer market and economic sensitivity. Analyst consensus is strongly bullish with 14 buys and no sells, supporting a favorable investment case for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
